New Enterprise Associates related stories
All articles and analysis
Data startup Igneous lands $25 mln Series CSeattle-based data startup Igneous Inc, has raised $25 million in Series C funding. WestRiver Group led the round with participation from other investors that included Madrona Venture Group, New Enterprise Associates, Vulcan Capital and Redpoint Ventures.
- BlackBird raises $10 mln in NEA-led deal
BlackBird said it raised $10 million of Series A capital in a deal led by New Enterprise Associates. As part of the deal, NEA Partner Jonathan Golden will join the board.
BDC, NEA to vote for $1.31 bln acquisition of ClementiaBDC Capital's Healthcare Venture Fund and New Enterprises Associates (NEA) have agreed to vote in favour of Ipsen's acquisition of Clementia Pharmaceuticals (Nasdaq: CMTA). Last month, France's Ipsen agreed to acquire /canada/2019/02/ipsen-to-buy-clementia-pharmaceuticals-in-1-31-bln-deal/ Clementia, a Montréal-based developer of treatments for ultra-rare bone disorders and other diseases, for US$1.31 billion ($1.72 billion). BDC and NEA, which respectively own about 14 percent and 7.1 percent of Clementia's issued and outstanding shares, join OrbiMed Advisors and other investors that have already indicated approval of the deal. These shareholders together hold a 51.7 percent interest in the company.
- Hearing aid maker Eargo fetches more than $52 mln Series D
Eargo, a hearing aid maker, has secured more than $52 million in Series D funding. The investors were New Enterprise Associates, the Charles and Helen Schwab Foundation, Nan Fung Life Sciences, Maveron and Future Fund.
PEI Awards 2018: Americas winnersThe Americas champions, including firms, limited partners, lawyers and many more.
- NEA targets $3.6 bln for 17th fund
New Enterprise Associates is seeking to raise $3.6 billion for its 17th fund, according to an SEC filing. https://www.sec.gov/Archives/edgar/data/1768564/000176856419000001/xslFormDX01/primary_doc.xml?utm_source=newsletter&utm_medium=email&utm_campaign=newsletter_axiosprorata&stream=top The venture firm invests in healthcare and technology.
- Landit nabs $13 mln in WeWork-led round
Landit, a tech platform "that increases the success of women," has secured $13 million in Series A funding. WeWork led the round with participation from other investors that included New Enterprise Associates, Valo Ventures, Workday Ventures and Gingerbread Capital.
- Tulip raises $18.4 mln
Somerville, Massachusetts-based Tulip, a provider of a manufacturing app platform, announced it has raised an $18.4 million Series B round. Vertex Ventures US led the round, which was also backed by New Enterprise Associates and Pitango Ventures. As part of the funding, Sandeep Bhadra, a Vertex Ventures partner, will join the board.
Ipsen to buy Clementia Pharmaceuticals in $1.31 bln dealIpsen has agreed to acquire Clementia Pharmaceuticals (Nasdaq: CMTA), a Montréal-based developer of treatments for people with ultra-rare bone disorders and other diseases. Ipsen agreed to pay US$25 per share in cash upfront plus deferred payments, bringing the total consideration to US$1.31 billion ($1.73 billion). Ipsen, a Paris-based specialty biopharmaceutical group, said the purchase of Clementia's drug candidate palovarotene and other assets will boost its rare disease portfolio. Founded in 2010 by CEO Clarissa Desjardins, Clementia was venture-capital-backed before going public /canada/2017/08/3468640/ in 2017, raising $174 million. Several investors, including BDC Capital, New Enterprise Associates and OrbiMed Advisors, continue to hold stakes in the company.